Genetic testing for the BRCA1 gene and circulating tumor DNA monitoring via Signatera blood tests shape cancer surveillance protocols for young survivors like Chance Osborne, who faced a triple-negative breast cancer diagnosis at age 24 despite rigorous bi-annual imaging, usatoday.com reported in October 2026. Osborne’s case highlights the rising incidence of breast, liver, ovarian, and colorectal cancers among Gen X and millennials documented by American Cancer Society research.
Chance Osborne Discovers Triple-Negative Breast Cancer After Clean MRI Scan
Chance Osborne discovered a lump on her chest while tanning on a beach in Florida in early 2021, just two weeks after receiving a clear breast MRI result. She was 24 years old at the time. Her family medical history included her mother dying of ovarian cancer in 2011, when Osborne was 14 years old, alongside multiple maternal aunts battling various forms of cancer. Genetic counseling at age 18 confirmed she carried the BRCA1 gene, prompting her medical team to initiate bi-annual breast MRIs and alternating mammograms or ultrasounds starting at age 20.
Despite those early detection measures, the newly discovered lump proved to be aggressive triple-negative breast cancer. Osborne noted that the tumor nearly doubled in size within a two-week span between self-discovery and her clinical appointment. American Cancer Society data indicates that breast cancer diagnoses exceed 300,000 annually in the United States, killing over 40,000 women in 2026 alone, while seventeen distinct cancer types show rising rates specifically among Gen X and millennial demographics.
Dr. Ruemu Birhiray, an oncologist and hematologist at Hematology Oncology of Indiana/American Oncology Network, emphasizes that many people mistakenly believe a direct family history is mandatory to develop breast cancer. Most cases remain curable if detected early through imaging tools like mammograms. Dr. Birhiray acknowledges that current screening methods are not completely infallible, but stresses that annual mammograms combined with monthly self-breast exams provide vital risk-identification pathways.
Following her diagnosis, Osborne underwent extensive medical interventions starting with chemotherapy from April to August 2021. Her treatment plan proceeded with surgery, radiation therapy, a double mastectomy involving failed reconstruction, and a preventative total hysterectomy driven by her family history and BRCA1 status. She subsequently completed 372 days of prescribed medication, achieving a five-year survival milestone by late 2026.
Signatera Circulating Tumor DNA Tests Provide Ongoing Surveillance For Cancer Relapses
Social media exposure during her treatment introduced Osborne to Signatera, a circulating tumor DNA test designed to detect potential cancer relapses earlier. She advocated for her physicians to order the blood tests for personal peace of mind, completing 15 negative screenings over a three-year span. Osborne undergoes the blood draw every three months and plans to transition to bi-annual testing upon reaching seven years of confirmed cancer-free status, following guidance from her oncologist.
“You might be able to do something about it sooner rather than later before it establishes itself,” Dr. Birhiray said regarding early recurrence detection. Osborne acknowledges ongoing test anxiety while waiting for results but maintains that the certainty outweighs the distress of ignorance.
BRCA1 Genetic Testing Empowers Patients Despite Persistent Grief and Survivorship Guilt
July 2026 marked a poignant timeline milestone for Osborne, surpassing the duration of her mother’s life spent with her before the 2011 death. Coping with her own cancer survivorship while processing maternal grief introduced complex emotional layers, including survivorship guilt. She now campaigns publicly for widespread genetic testing to establish individual risk baselines.
“Finding out this information about your DNA is not intended to be scary,” Osborne said. “It’s intended to be empowering and enable you to make decisions to save your own life.” She emphasizes that youth and the absence of known family illness do not eliminate individual cancer risk.
Frequently Asked Questions About BRCA1 Testing and Breast Cancer Screening
What does carrying the BRCA1 gene mutation mean for cancer risk?
Carrying the BRCA1 gene increases a person’s risk of developing both breast and ovarian cancers. Individuals who test positive often begin specialized imaging protocols, such as alternating breast MRIs and mammograms, at an earlier age.
How common is breast cancer among younger populations?
American Cancer Society research published in 2024 shows that breast cancer, along with 16 other cancer types, is rising across Gen X and millennial generations. Nationally, over 300,000 women receive breast cancer diagnoses each year.
What is a Signatera test used for in cancer survivorship?
Signatera is a circulating tumor DNA test utilized by oncologists to help detect potential cancer relapses earlier through blood-based biomarker monitoring. Patients like Chance Osborne use the results every three months to track recurrence risks during survivorship.
Are family histories required to develop breast cancer?
Dr. Ruemu Birhiray states that a common misconception is that a family history of cancer is required to contract the disease. Many patients develop breast cancer without any documented prior family lineage of the illness.
Keep reading